Targeted Therapy for Newly Diagnosed Ocular Adnexal Marginal Zone Lymphoma with Chlamydophila Psittaci-eradicating Doxycycline

This clinical trial aims to find out how well a targeted therapy works for patients newly diagnosed with a type of eye cancer called Ocular Adnexal Marginal Zone Lymphoma (OAMZL). The therapy focuses on eradicating a specific bacteria, Chlamydophila psittaci (Cp), using a prolonged course of an antibiotic called doxycycline. After the treatment, patients are monitored for any signs of infection re-occurrence, and if needed, they receive antibiotic re-treatment. The goal of this study is to improve the treatment approach for this condition, potentially enhancing patient care and addressing current challenges. During this phase 2 trial, participants receive doxycycline as their first-line treatment. The study measures the success of this treatment by tracking the 'progression-free survival' (PFS) over a 2-year period. This means the study monitors patients from the start of their treatment to see if their condition worsens or if they experience any recurrence of the infection. The primary outcome of the study is to evaluate how many patients remain progression-free after this treatment strategy.